CN1504484A - 修饰猪血白蛋白代替人血白蛋白的制备方法 - Google Patents
修饰猪血白蛋白代替人血白蛋白的制备方法 Download PDFInfo
- Publication number
- CN1504484A CN1504484A CNA021446792A CN02144679A CN1504484A CN 1504484 A CN1504484 A CN 1504484A CN A021446792 A CNA021446792 A CN A021446792A CN 02144679 A CN02144679 A CN 02144679A CN 1504484 A CN1504484 A CN 1504484A
- Authority
- CN
- China
- Prior art keywords
- peg
- albumin
- porcine
- add
- cyanuric chloride
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000009027 Albumins Human genes 0.000 title claims abstract description 82
- 108010088751 Albumins Proteins 0.000 title claims abstract description 82
- 210000004369 blood Anatomy 0.000 title claims abstract description 72
- 239000008280 blood Substances 0.000 title claims abstract description 72
- 238000002360 preparation method Methods 0.000 title claims abstract description 22
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims abstract description 71
- MGNCLNQXLYJVJD-UHFFFAOYSA-N cyanuric chloride Chemical compound ClC1=NC(Cl)=NC(Cl)=N1 MGNCLNQXLYJVJD-UHFFFAOYSA-N 0.000 claims abstract description 29
- 230000004048 modification Effects 0.000 claims abstract description 20
- 238000012986 modification Methods 0.000 claims abstract description 20
- 230000004913 activation Effects 0.000 claims abstract description 12
- 230000008878 coupling Effects 0.000 claims abstract description 10
- 238000010168 coupling process Methods 0.000 claims abstract description 10
- 238000005859 coupling reaction Methods 0.000 claims abstract description 10
- 229920001223 polyethylene glycol Polymers 0.000 claims description 35
- 238000003756 stirring Methods 0.000 claims description 27
- 108091006905 Human Serum Albumin Proteins 0.000 claims description 21
- 102000008100 Human Serum Albumin Human genes 0.000 claims description 21
- 239000007788 liquid Substances 0.000 claims description 20
- 238000000502 dialysis Methods 0.000 claims description 18
- 238000001953 recrystallisation Methods 0.000 claims description 18
- 238000004108 freeze drying Methods 0.000 claims description 15
- 238000002425 crystallisation Methods 0.000 claims description 14
- 230000008025 crystallization Effects 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 13
- 239000002244 precipitate Substances 0.000 claims description 11
- 102000001554 Hemoglobins Human genes 0.000 claims description 10
- 108010054147 Hemoglobins Proteins 0.000 claims description 10
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical class OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- 238000013016 damping Methods 0.000 claims description 7
- 239000000706 filtrate Substances 0.000 claims description 7
- 239000012530 fluid Substances 0.000 claims description 7
- 239000011521 glass Substances 0.000 claims description 7
- 230000003252 repetitive effect Effects 0.000 claims description 7
- 238000010521 absorption reaction Methods 0.000 claims description 5
- 229910021538 borax Inorganic materials 0.000 claims description 5
- UQGFMSUEHSUPRD-UHFFFAOYSA-N disodium;3,7-dioxido-2,4,6,8,9-pentaoxa-1,3,5,7-tetraborabicyclo[3.3.1]nonane Chemical compound [Na+].[Na+].O1B([O-])OB2OB([O-])OB1O2 UQGFMSUEHSUPRD-UHFFFAOYSA-N 0.000 claims description 5
- 238000001914 filtration Methods 0.000 claims description 5
- 239000006060 molten glass Substances 0.000 claims description 5
- 230000008569 process Effects 0.000 claims description 5
- 210000002966 serum Anatomy 0.000 claims description 5
- 239000004328 sodium tetraborate Substances 0.000 claims description 5
- 235000010339 sodium tetraborate Nutrition 0.000 claims description 5
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims description 4
- 239000012153 distilled water Substances 0.000 claims description 4
- 238000012856 packing Methods 0.000 claims description 4
- 238000012546 transfer Methods 0.000 claims description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims description 3
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 claims description 2
- 238000009835 boiling Methods 0.000 claims description 2
- 239000001110 calcium chloride Substances 0.000 claims description 2
- 229910001628 calcium chloride Inorganic materials 0.000 claims description 2
- 239000001569 carbon dioxide Substances 0.000 claims description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 239000003208 petroleum Substances 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 238000001556 precipitation Methods 0.000 claims description 2
- 238000010992 reflux Methods 0.000 claims description 2
- 229920006395 saturated elastomer Polymers 0.000 claims description 2
- 239000006228 supernatant Substances 0.000 claims description 2
- 238000012544 monitoring process Methods 0.000 claims 2
- 238000011160 research Methods 0.000 abstract description 5
- 230000005847 immunogenicity Effects 0.000 abstract description 4
- 102000007562 Serum Albumin Human genes 0.000 abstract description 3
- 108010071390 Serum Albumin Proteins 0.000 abstract description 3
- 239000003607 modifier Substances 0.000 abstract description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract description 3
- 230000009897 systematic effect Effects 0.000 abstract description 2
- 231100000027 toxicology Toxicity 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 description 17
- 238000012360 testing method Methods 0.000 description 12
- 108090000623 proteins and genes Proteins 0.000 description 11
- 238000006243 chemical reaction Methods 0.000 description 10
- 102000004169 proteins and genes Human genes 0.000 description 10
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 8
- 229940098773 bovine serum albumin Drugs 0.000 description 8
- 229910052801 chlorine Inorganic materials 0.000 description 7
- 125000001309 chloro group Chemical group Cl* 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 210000002381 plasma Anatomy 0.000 description 7
- 241000700605 Viruses Species 0.000 description 6
- 239000000427 antigen Substances 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 102000036639 antigens Human genes 0.000 description 5
- 108091007433 antigens Proteins 0.000 description 5
- 238000010241 blood sampling Methods 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- -1 polyoxyethylene Polymers 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 241000709721 Hepatovirus A Species 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 230000003204 osmotic effect Effects 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- 241000233855 Orchidaceae Species 0.000 description 3
- 125000003277 amino group Chemical group 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000012797 qualification Methods 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- 210000001835 viscera Anatomy 0.000 description 3
- 208000030507 AIDS Diseases 0.000 description 2
- 206010002198 Anaphylactic reaction Diseases 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 108090000371 Esterases Proteins 0.000 description 2
- 241000711549 Hepacivirus C Species 0.000 description 2
- 241000700721 Hepatitis B virus Species 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 125000003368 amide group Chemical group 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000036783 anaphylactic response Effects 0.000 description 2
- 208000003455 anaphylaxis Diseases 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000005611 electricity Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 229920001427 mPEG Polymers 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- JMANVNJQNLATNU-UHFFFAOYSA-N oxalonitrile Chemical compound N#CC#N JMANVNJQNLATNU-UHFFFAOYSA-N 0.000 description 2
- 108010027841 pegademase bovine Proteins 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- PITLRSDLRTWZGP-UHFFFAOYSA-N 2-(oxiran-2-yl)acetonitrile Chemical compound N#CCC1CO1 PITLRSDLRTWZGP-UHFFFAOYSA-N 0.000 description 1
- LRWZZZWJMFNZIK-UHFFFAOYSA-N 2-chloro-3-methyloxirane Chemical compound CC1OC1Cl LRWZZZWJMFNZIK-UHFFFAOYSA-N 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- LTGPFZWZZNUIIK-LURJTMIESA-N Lysol Chemical compound NCCCC[C@H](N)CO LTGPFZWZZNUIIK-LURJTMIESA-N 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 208000000260 Warts Diseases 0.000 description 1
- DPDMMXDBJGCCQC-UHFFFAOYSA-N [Na].[Cl] Chemical compound [Na].[Cl] DPDMMXDBJGCCQC-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 239000010836 blood and blood product Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 229940125691 blood product Drugs 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 231100000132 chronic toxicity testing Toxicity 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 230000002016 colloidosmotic effect Effects 0.000 description 1
- 239000007822 coupling agent Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- WDJUZGPOPHTGOT-XUDUSOBPSA-N digitoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)CC5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O WDJUZGPOPHTGOT-XUDUSOBPSA-N 0.000 description 1
- 229960000648 digitoxin Drugs 0.000 description 1
- 238000002086 displacement chromatography Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- GKIPXFAANLTWBM-UHFFFAOYSA-N epibromohydrin Chemical compound BrCC1CO1 GKIPXFAANLTWBM-UHFFFAOYSA-N 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000011086 glassine Substances 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 150000008131 glucosides Chemical class 0.000 description 1
- 125000003827 glycol group Chemical group 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 210000003677 hemocyte Anatomy 0.000 description 1
- 229940000351 hemocyte Drugs 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 208000005252 hepatitis A Diseases 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 230000000951 immunodiffusion Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- YDTFRJLNMPSCFM-YDALLXLXSA-M levothyroxine sodium anhydrous Chemical compound [Na+].IC1=CC(C[C@H](N)C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 YDTFRJLNMPSCFM-YDALLXLXSA-M 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 231100001252 long-term toxicity Toxicity 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000012434 nucleophilic reagent Substances 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 239000000123 paper Substances 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000001902 propagating effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 238000011046 pyrogen test Methods 0.000 description 1
- 238000000163 radioactive labelling Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 201000010153 skin papilloma Diseases 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 230000001550 time effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 238000005829 trimerization reaction Methods 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 description 1
- 229960005080 warfarin Drugs 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 206010048282 zoonosis Diseases 0.000 description 1
Landscapes
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
PEG——19004℃ 25℃ 37℃ | PEG——50004℃ 25℃ 37℃ | |
修饰氨基酸每分子 | 25 53 34 | 19 55 30 |
修饰率% | 42 89 56 | 32 91 52 |
豚鼠编号 | 色标 | 第一次注射 | 一周后 | 二周后 | 四周后 | 过敏反应 |
1 | 头兰 | 10mg | 10mg | 10mg | 20mg | —— |
2 | 花 | 10mg | 10mg | 10mg | 20mg | —— |
3 | 尾兰 | 10mg | 10mg | 10mg | 20mg | —— |
4 | 腰兰 | 10mg | 10mg | 10mg | 20mg | +死亡 |
5 | 腿兰 | 10mg | 10mg | 10mg | 20mg | + |
6 | 黑 | 10mg | 10mg | 10mg | 20mg | + |
Claims (2)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNA021446792A CN1504484A (zh) | 2002-12-04 | 2002-12-04 | 修饰猪血白蛋白代替人血白蛋白的制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNA021446792A CN1504484A (zh) | 2002-12-04 | 2002-12-04 | 修饰猪血白蛋白代替人血白蛋白的制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN1504484A true CN1504484A (zh) | 2004-06-16 |
Family
ID=34232058
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNA021446792A Pending CN1504484A (zh) | 2002-12-04 | 2002-12-04 | 修饰猪血白蛋白代替人血白蛋白的制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1504484A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102707069A (zh) * | 2012-06-04 | 2012-10-03 | 南京巴傲得生物科技有限公司 | 免疫组化二抗试剂盒 |
-
2002
- 2002-12-04 CN CNA021446792A patent/CN1504484A/zh active Pending
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102707069A (zh) * | 2012-06-04 | 2012-10-03 | 南京巴傲得生物科技有限公司 | 免疫组化二抗试剂盒 |
CN102707069B (zh) * | 2012-06-04 | 2015-04-08 | 南京巴傲得生物科技有限公司 | 一种免疫组化二抗试剂盒的制备方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN105879021A (zh) | 使免疫原性组合物稳定且抑制其沉淀的新颖调配物 | |
US7700746B2 (en) | Filtration material | |
CN1610560A (zh) | 多价脑膜炎球菌多糖-蛋白质缀合疫苗 | |
CN101687048A (zh) | 可水解的聚合fmoc-连接体 | |
CN102614843B (zh) | 蛋白a免疫吸附材料及其制备方法 | |
CN102247817B (zh) | 一种以分子簇为功能基的内毒素吸附剂及其制备方法 | |
CN110845636B (zh) | 一种去除细菌多糖中的内毒素的方法 | |
CN1504484A (zh) | 修饰猪血白蛋白代替人血白蛋白的制备方法 | |
US7038016B2 (en) | Methods for purification of an activated PEG solution and for the synthesis of a modified hemoglobin solution | |
CN1284797C (zh) | 人重组组织因子的构建表达、纯化方法及其应用 | |
CN1749274A (zh) | 一种新的重组人干扰素α2b的分离纯化方法 | |
JPS61502680A (ja) | 生化学的薬剤及びその製造方法 | |
EP0481013B1 (en) | A composition for removing or inactivating harmful components in blood or other extracellular body fluids | |
CN1660443A (zh) | 甲氧基聚乙二醇衍生物的用途、经化学修饰的通用型红细胞及其制备方法 | |
Hightower et al. | Plasma expander and blood storage effects on capillary perfusion in transfusion after hemorrhage | |
CN101757029A (zh) | 一种从牛脾脏中提取转移因子的方法 | |
CN1209163C (zh) | 脑膜炎球菌疫苗及其制备方法 | |
CN1403813A (zh) | 旋毛虫病快速诊断试纸条 | |
Debenham et al. | Homologous whole blood transfusion during treatment of severe anemia in a chimpanzee (Pan troglodytes) | |
DE3939470A1 (de) | Peptide und antikoerper gegen peptide, welche zur diagnose und zur verhuetung der b19-infektion verwendbar sind | |
CN1064049C (zh) | 血小板生成素制备工艺 | |
CN1544468A (zh) | 以酰胺键连接的聚乙二醇-干扰素及其制法和用途 | |
CN1683006A (zh) | 一种提高动物免疫功能的苷肽注射液 | |
KR20190129148A (ko) | 규조류 및 쿠커비투릴을 이용한 병원체 농축 방법 | |
RU2111013C1 (ru) | Способ получения антител к арбовирусам комплекса калифорнийского энцефалита и батаи |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
ASS | Succession or assignment of patent right |
Owner name: GOU SHIJIN Free format text: FORMER OWNER: SHENYANG NANKE PATENT TECHNOLOGY DEVELOPMENT CORP. Effective date: 20050819 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20050819 Address after: Dongling District of Shenyang city of Liaoning Province River Station Township village ahead of 34-55 Applicant after: Gou Shijin Address before: Dongling District of Shenyang city of Liaoning Province River Station Township Village forward Applicant before: Shenyang Nanke Patent Technology Development Corp. |
|
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
WD01 | Invention patent application deemed withdrawn after publication |